Both normal and leukemic B lymphocytes express multiple isoforms of the human Aiolos gene. 2001

J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
Turku Graduate School of Biomedical Sciences and Department of Medical Microbiology, University of Turku, Turku, Finland. jussi.liippo@utu.fi

Aiolos is a chromatin remodeling transcription regulator that plays an antiproliferative role in B lymphocyte function. In contrast to the related Ikaros factors, mammalian Aiolos has not been reported to generate splice variants. In addition, although human leukemic lymphoblasts express non-DNA-binding Ikaros isoforms with potential dominant negative effect on other interacting factors,the role of Aiolos in human lymphoid disorders has remained obscure. To address the question, why Aiolos should delineate from Ikaros in such a marked way, we have here analyzed whether also human Aiolos could generate alternate isoforms. According to the results obtained, both normal and neoplastic B lineage cells were found to express at least five novel Aiolos variants. Also structurally dominant negative variants with less than three DNA-binding domains were identified. In conclusion, given the multiplicity of also human Aiolos isoforms and thereby the evidently more intricate contribution of Aiolos to the chromatin remodeling machinery, it is suggested, that not only Ikaros, but also Aiolos could participate in a more versatile manner in the regulation of B lymphocyte function.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D015534 Trans-Activators Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins. Nuclear Trans-Acting Factor,Trans-Acting Factors,Trans-Acting Factor,Trans-Activator,Transactivator,Transactivators,Factor, Nuclear Trans-Acting,Factor, Trans-Acting,Factors, Trans-Acting,Nuclear Trans Acting Factor,Trans Acting Factor,Trans Acting Factors,Trans Activator,Trans Activators,Trans-Acting Factor, Nuclear
D017398 Alternative Splicing A process whereby multiple RNA transcripts are generated from a single gene. Alternative splicing involves the splicing together of other possible sets of EXONS during the processing of some, but not all, transcripts of the gene. Thus a particular exon may be connected to any one of several alternative exons to form a mature RNA. The alternative forms of mature MESSENGER RNA produce PROTEIN ISOFORMS in which one part of the isoforms is common while the other parts are different. RNA Splicing, Alternative,Splicing, Alternative,Alternate Splicing,Nested Transcripts,Alternate Splicings,Alternative RNA Splicing,Alternative RNA Splicings,Alternative Splicings,Nested Transcript,RNA Splicings, Alternative,Splicing, Alternate,Splicing, Alternative RNA,Splicings, Alternate,Splicings, Alternative,Splicings, Alternative RNA,Transcript, Nested,Transcripts, Nested
D051740 Ikaros Transcription Factor A transcription factor that plays a role as a key regulator of HEMATOPOIESIS. Aberrant Ikaros expression has been associated with LYMPHOBLASTIC LEUKEMIA. Ikaros Protein,Transcription Factor, Ikaros

Related Publications

J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
November 2009, British journal of haematology,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
January 1965, Enzymologia biologica et clinica,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
January 1963, The Journal of laboratory and clinical medicine,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
February 1982, Clinica chimica acta; international journal of clinical chemistry,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
February 1993, Blood,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
September 1999, European journal of immunology,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
August 1994, Cancer research,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
January 1981, Panminerva medica,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
February 1982, The Journal of experimental medicine,
J Liippo, and K P Nera, and E Veistinen, and A Lähdesmäki, and V Postila, and E Kimby, and P Riikonen, and L Hammarström, and J Pelkonen, and O Lassila
April 1980, Clinical immunology and immunopathology,
Copied contents to your clipboard!